How Echinocandins Work Against Fungal Infections

Echinocandins are a class of antifungal drugs that work by dismantling the fungal cell wall, a structure that human cells lack entirely. That selectivity gives them a remarkably clean safety profile compared with older antifungals, and it is why global guidelines now recommend them as first-line therapy for the most dangerous bloodstream yeast infections. Four agents currently make up the class: caspofungin (the first approved, in 2001), micafungin, anidulafungin, and the newest arrival, rezafungin. Their story is one of genuine clinical success tempered by emerging resistance and a few biological quirks that keep researchers busy.

How Echinocandins Kill Fungi

Fungal cells rely on a mesh of sugar-chain polymers in their cell wall to hold everything together. The most important of these polymers is a molecule called beta-(1,3)-D-glucan, which acts like structural rebar. An enzyme embedded in the fungal cell membrane, known as 1,3-beta-glucan synthase, is responsible for producing it.¹ Echinocandins bind to a specific part of that enzyme (the Fks1p subunit) and shut down glucan production. Without fresh glucan, the cell wall weakens, the fungus cannot maintain its internal pressure, and the cell bursts.²

Because mammalian cells have no cell wall at all, they have no version of this enzyme. That is the biological reason echinocandins cause so few side effects in people: the drug’s target simply does not exist in the patient’s body.³

Which Fungi They Work Against

Echinocandins are most potent against Candida species, the yeasts responsible for the majority of serious hospital-acquired fungal infections. Against Candida, they are fungicidal, meaning they actively kill the organism rather than just stopping its growth. That activity extends to strains that have become resistant to azole antifungals like fluconazole, which makes echinocandins especially valuable when resistance narrows the options.⁴ Against Aspergillus, the mold behind most invasive mold infections in immunocompromised patients, echinocandins are fungistatic: they stop the mold from growing but do not kill it outright. That distinction matters for how they get used clinically, often as part of combination regimens against Aspergillus rather than as standalone treatment.

The class does have blind spots. Fungi that build their walls with different polymers, such as Cryptococcus neoformans (which causes cryptococcal meningitis) and the Mucorales molds (which cause mucormycosis), are intrinsically resistant. Echinocandins are not useful against those pathogens.

First-Line Status for Candidemia

When Candida reaches the bloodstream, the resulting condition, candidemia, carries a mortality rate that can exceed 40 percent in critically ill patients. Current global guidelines strongly recommend all four echinocandins as first-line therapy for candidemia, including against Candida auris, a multidrug-resistant species that has alarmed public health agencies worldwide.⁵ The reasoning is a combination of broad-spectrum Candida coverage, a favorable safety profile, and minimal drug-drug interactions.

Echinocandins also play a central role in managing invasive candidiasis in patients with liver disease and liver transplants, populations where antifungal choice is complicated by organ dysfunction and heavy use of other medications.⁶ Their limited hepatic metabolism and low interaction potential make them easier to use in these settings than azoles, which are processed heavily by the liver and interfere with many other drugs.

How They Compare with Fluconazole

Fluconazole is cheap, orally available, and has been a workhorse antifungal for decades. So why switch to an IV-only echinocandin? The evidence is nuanced. A landmark trial found that anidulafungin achieved treatment success in about 76 percent of candidemia patients at the end of IV therapy, compared with 60 percent for fluconazole.⁷ A separate study looking at persistent candidemia found echinocandins were more effective at clearing yeast from the bloodstream.⁸

However, a propensity-matched analysis looking specifically at candidemia caused by Candida species known to be susceptible to fluconazole found no significant difference in 60-day mortality between the two treatments. In that study, septic shock was the factor that independently predicted death, not the choice of antifungal.⁹ The practical takeaway: for infections caused by fluconazole-susceptible strains in patients who are not critically ill, fluconazole may still be reasonable, and switching to oral fluconazole after initial IV echinocandin therapy is a common step-down strategy. But when the species is unknown, resistance is suspected, or the patient is severely ill, echinocandins are the safer starting bet.

Safety and Side Effects

Compared with amphotericin B, the older antifungal that echinocandins often replace, the toxicity difference is stark. Amphotericin B is notorious for kidney damage, infusion-related fevers, and electrolyte disturbances. Studies of caspofungin showed equivalent efficacy to amphotericin B against candidemia with substantially fewer toxic effects.¹⁰ Clinical trials across the class have consistently reported a low incidence of adverse events.¹¹

That said, they are not side-effect-free. The most clinically relevant reaction is a histamine-mediated infusion reaction that can occur during IV administration. Symptoms range from flushing and rash to, in rare cases, more severe events. One documented case involved flash pulmonary edema during anidulafungin infusion, believed to be linked to histamine release.¹² Slowing the infusion rate typically prevents or manages these reactions. Liver enzyme elevations can occur, usually mild and transient, and are monitored in clinical practice but rarely require stopping treatment.

Echinocandin Resistance

For the first decade after their introduction, echinocandin resistance was essentially a non-problem. That is changing. The primary resistance mechanism involves mutations in the FKS genes that encode the drug’s target enzyme. When the enzyme’s shape changes even slightly at certain “hot spot” regions, echinocandins can no longer bind effectively. In a large screen of over a thousand Candida glabrata isolates (now reclassified as Nakaseomyces glabratus), researchers found 51 isolates with hot spot mutations, and nearly all were resistant to at least one echinocandin by standard testing.¹³ These mutations are not just a laboratory curiosity: in a clinical study, the presence of an FKS mutation was the only independent risk factor for echinocandin treatment failure, outweighing other variables like the measured drug concentration needed to inhibit the organism.¹⁴

Candida auris has added urgency to the resistance conversation. While echinocandin resistance in C. auris remains uncommon, it has been creeping upward. Surveillance of clinical isolates in New York showed echinocandin resistance rising from 0 to 4 percent between 2016 and 2020.¹⁵ A hospital outbreak in Italy documented the evolution of pandrug-resistant C. auris, with echinocandin resistance emerging through independent FKS1 mutations after prolonged treatment with caspofungin or anidulafungin.¹⁶ Acquired resistance in C. auris is still rare overall, but the fact that it can emerge under treatment pressure through the same FKS mutation pathway seen in other Candida species is concerning.¹⁷

One wrinkle worth noting: the rate at which resistance mutations arise may differ among the three older echinocandins. In laboratory experiments with C. glabrata, mutations at certain hot spot positions emerged more frequently after exposure to anidulafungin or micafungin than after exposure to caspofungin.¹⁸ Whether that translates to meaningful clinical differences in resistance emergence is still debated.

Activity Against Biofilms

Candida does not just float freely in the bloodstream. It readily forms biofilms on medical devices: catheters, prosthetic heart valves, joint implants. Biofilms are structured communities of organisms embedded in a gooey matrix that makes them dramatically harder to treat. Most antifungals struggle to penetrate or kill cells within a biofilm, but echinocandins are an exception. In a rat model using implanted catheters, all three older echinocandins significantly reduced Candida cell counts on the devices.¹⁹

This has practical implications for catheter management. When a patient develops candidemia, the standard recommendation is to remove the infected catheter. But sometimes removal is not feasible, whether because of the patient’s anatomy, clotting risks, or limited vascular access. In those situations, echinocandin-based lock therapy, where a concentrated drug solution is instilled directly into the catheter lumen and left to dwell, has shown promise. Micafungin in particular demonstrated significant activity against both young and mature biofilms of Candida albicans and Candida glabrata on silicone surfaces, with the effect persisting for up to three days.²⁰ Rezafungin (then called CD101 during development) also showed potent activity against both early and mature biofilms in preclinical testing.²¹

The Paradoxical Effect

One of the stranger phenomena in echinocandin pharmacology is what researchers call the “paradoxical effect.” At concentrations around the minimum inhibitory level, echinocandins suppress fungal growth effectively. But at much higher concentrations, certain Candida isolates actually resume growing.²² It sounds alarming, but a few things are worth understanding. The effect is primarily observed in the laboratory, not at the bedside. It varies by species and by echinocandin: a study of 60 Candida bloodstream isolates from cancer patients found paradoxical growth was more frequent with caspofungin than with micafungin or anidulafungin, and was essentially absent in C. glabrata.²³ The clinical significance remains unclear. The paradoxical effect is not the same thing as resistance: the organisms showing it are fully susceptible at standard drug concentrations. It is an active area of study, but clinicians generally do not adjust treatment based on it.

Echinocandins in Neonates

Invasive candidiasis in premature babies carries devastating mortality rates, and antifungal options in this population are limited. Amphotericin B has been the traditional choice, but echinocandins are increasingly studied and used. All three older agents have characteristics that suit the neonatal intensive care unit: activity against a broad range of Candida strains, biofilm coverage (important given the frequent use of central lines in these tiny patients), and a safety profile that appears favorable.²⁴

Dosing neonates is tricky because they metabolize drugs differently than older children or adults. Studies have worked out appropriate weight-based dosing. A phase 2 trial of micafungin at 8 mg/kg daily in neonates and young infants with invasive candidiasis found infection resolution in about 87 percent of those treated for at least 14 days. A fifth of patients had transient liver enzyme elevations, but the drug was otherwise well tolerated.²⁵ Anidulafungin has also been studied in this group: at a maintenance dose of 1.5 mg/kg/day, drug exposure levels in neonates were similar to those achieved with equivalent weight-based dosing in older children and standard adult dosing, with no drug-related serious adverse events.²⁶

Combination Therapy with Other Antifungals

Because echinocandins attack the cell wall while azoles and amphotericin B target different parts of the fungal cell, combining them with other antifungal classes is a logical strategy, especially for resistant infections. In laboratory studies of Aspergillus, pairing echinocandins with either amphotericin B or voriconazole produced strong synergy, meaning the combination worked far better than either drug alone.²⁷ In an animal model of invasive pulmonary aspergillosis, a triazole-echinocandin combination was particularly beneficial against azole-resistant isolates, producing fungal burden reductions that neither drug achieved on its own.²⁸

Similar synergy has been demonstrated for Candida. When fluconazole was paired with anidulafungin against fluconazole-resistant Candida parapsilosis complex isolates, the combination dramatically lowered the drug concentrations needed for each agent. Itraconazole-echinocandin pairings showed comparable results.²⁹ Translating in vitro synergy to routine clinical protocols requires more randomized trial data, which is a recurring gap in the antifungal field. But for severely ill patients failing single-agent therapy, combination approaches already happen at the bedside.

Rezafungin and the Once-Weekly Dosing Model

Every echinocandin before rezafungin requires daily IV infusion. For a hospitalized patient, that is manageable, but it effectively tethers treatment to the hospital stay or demands daily outpatient infusion visits. Rezafungin was engineered for a much longer half-life, roughly 152 hours in patients with invasive candidiasis, compared to the 10-to-17-hour range typical of the older agents.³⁰ That allows once-weekly dosing: a single infusion maintains effective drug levels for days.

Approved by the FDA in 2023, rezafungin is recommended alongside the three older echinocandins as first-line therapy for candidemia.³¹ The weekly schedule could reshape outpatient treatment of serious fungal infections and may facilitate earlier hospital discharge. It also has very limited metabolism through the liver enzyme systems that process most other drugs, which keeps drug interactions to a minimum.

How Resistance Gets Detected

Knowing whether a Candida isolate is susceptible to echinocandins requires laboratory testing, and the field has invested real effort in making those tests reliable and interpretable. Two major systems exist for determining breakpoints, the drug concentrations that distinguish susceptible from resistant organisms. Both produce comparable results for echinocandins across Candida species, with agreement above 90 percent for most drug-species combinations.³²

What matters more in clinical practice is the recognition that the standard susceptibility number alone can be misleading. Revised species-specific breakpoints were introduced because the original one-size-fits-all threshold missed some resistant isolates while overcalling resistance in others.³³ And because FKS mutations are so tightly linked to treatment failure, some laboratories now perform molecular testing for those mutations alongside traditional susceptibility testing. For C. glabrata in particular, commercial testing methods have been validated as suitable for detecting echinocandin resistance, though multi-center validation is still being pursued to fully standardize the approach.³⁴

The broader picture is one of a diagnostic field catching up to clinical needs. As resistance becomes less rare, the speed and accuracy with which labs can flag it will increasingly affect patient outcomes. The convergence of phenotypic susceptibility testing and molecular resistance detection represents the direction the field is heading, and for echinocandins it is further along than for most other antifungal classes.